Guillain-Barre syndrome is an acute inflammatory immune-mediated polyradiculoneuropathy presenting typically with tingling, progressive weakness, and pain. Variants and formes frustes may complicate recognition. The best known variant is the sensory ataxic form of Miller Fisher syndrome, which also ...
Guillain-Barre syndrome is an acute inflammatory immune-mediated polyradiculoneuropathy presenting typically with tingling, progressive weakness, and pain. Variants and formes frustes may complicate recognition. The best known variant is the sensory ataxic form of Miller Fisher syndrome, which also affects the oculomotor nerves and the brain stem. Divergent pathologic mechanisms lead to demyelinating, axonal, or mixed demyelinating-axonal damage. In the demyelinating form, yet to be identified antigens are inferred by complement activation, myelin destruction, and macrophage-activated cleanup. In the axonal and Miller Fisher variants, gangliosides (GM1, GD1a, GQ1b) are targeted by immunoglobulins and share antigenic epitopes with some bacterial and viral antigens. Campylobacter jejuni infection is associated with an axonal-onset variant; affected patients commonly experience more rapid deterioration. Many other antecedent infectious agents have been recognized including the most recently identified, Zika virus. Supportive care remains the mainstay of therapy. Plasma exchange or intravenous immunoglobin hastens recovery. Combination immunotherapy is not more effective, and the efficacy of prolonged immunotherapy is unproven. One in 3 patients will have deterioration severe enough to require prolonged intensive care monitoring or mechanical ventilation. Full recovery is often seen; most patients regain ambulation, even in severe cases, but disability remains in up to 10% and perhaps more. Numerous challenges remain including early identification and control of infectious triggers, improved access of modern neurointensive care worldwide, and translating our understanding of pathogenesis into meaningful preventive or assistive therapies. This review provides a historical perspective at the centenary of the first description of the syndrome, insights into its pathogenesis, triage, initial immunotherapy, and management in the intensive care unit.
Guillain-Barre syndrome is an acute inflammatory immune-mediated polyradiculoneuropathy presenting typically with tingling, progressive weakness, and pain. Variants and formes frustes may complicate recognition. The best known variant is the sensory ataxic form of Miller Fisher syndrome, which also affects the oculomotor nerves and the brain stem. Divergent pathologic mechanisms lead to demyelinating, axonal, or mixed demyelinating-axonal damage. In the demyelinating form, yet to be identified antigens are inferred by complement activation, myelin destruction, and macrophage-activated cleanup. In the axonal and Miller Fisher variants, gangliosides (GM1, GD1a, GQ1b) are targeted by immunoglobulins and share antigenic epitopes with some bacterial and viral antigens. Campylobacter jejuni infection is associated with an axonal-onset variant; affected patients commonly experience more rapid deterioration. Many other antecedent infectious agents have been recognized including the most recently identified, Zika virus. Supportive care remains the mainstay of therapy. Plasma exchange or intravenous immunoglobin hastens recovery. Combination immunotherapy is not more effective, and the efficacy of prolonged immunotherapy is unproven. One in 3 patients will have deterioration severe enough to require prolonged intensive care monitoring or mechanical ventilation. Full recovery is often seen; most patients regain ambulation, even in severe cases, but disability remains in up to 10% and perhaps more. Numerous challenges remain including early identification and control of infectious triggers, improved access of modern neurointensive care worldwide, and translating our understanding of pathogenesis into meaningful preventive or assistive therapies. This review provides a historical perspective at the centenary of the first description of the syndrome, insights into its pathogenesis, triage, initial immunotherapy, and management in the intensive care unit.
참고문헌 (89)
Bull Memoires Soc Med Hopitaux Paris Guillain 40 1462 1916 Sur un syndrome de radiculonevrite avec hyperalbuminose du liquide cephalo-rachidien sans reaction cellulaire: remarques sur les caracteres cliniques et graphiques des reflexes tendineux
Willison 2016 GBS100: Celebrating a century of progress in Guillain-Barre syndrome
Front Microbiol Saiz 7 496 2016 Zika virus: the latest newcomer
10.1007/s12026-016-8816-8 Mahecha MP, Ojeda E, Vega DA, Sarmiento-Monroy JC, Anaya JM. Guillain-Barre syndrome in Colombia: where do we stand now [published online ahead of print July 15, 2016]? Immunol Res. http://dx.doi.org/10.1007/s12026-016-8816-8.
Gaz Hebd Med Landry 6 472 1859 Note sur la paralysie ascendante aigu
Wijdicks 219 2000 Neurological Eponyms The Guillain-Barre syndrome
Medicine (Baltimore) Haymaker 28 1 59 1949 10.1097/00005792-194902010-00003 The Landry-Guillain-Barre syndrome: a clinicopathologic report of 50 fatal cases and a critique of the literature
Mayo Clin Proc Wiederholt 39 427 1964 The Landry-Guillain-Barr'e-Strohl syndrome or polyradiculoneuropathy: historical review, report on 97 patients, and present concepts
Brain Griffin 118 pt 3 577 1995 10.1093/brain/118.3.577 Guillain-Barre syndrome in northern China: the spectrum of neuropathological changes in clinically defined cases
N Engl J Med van der Meche 326 17 1123 1992 10.1056/NEJM199204233261705 A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome
Neurology Hughes 61 6 736 2003 10.1212/WNL.61.6.736 Practice parameter: immunotherapy for Guillain-Barre syndrome; report of the Quality Standards Subcommittee of the American Academy of Neurology
Lancet Salmon 381 9876 1461 2013 10.1016/S0140-6736(12)62189-8 Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis
Nagarajan E, Rubin M, Wijdicks EFM, et al. Guillain-Barre syndrome after surgical procedures: predisposing factors and outcome. Neurol Clin Pract in revision.
Neurology Islam 74 7 581 2010 10.1212/WNL.0b013e3181cff735 Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh
Ann Neurol Ogawara 48 4 624 2000 10.1002/1531-8249(200010)48:4<624::AID-ANA9>3.0.CO;2-O Axonal Guillain-Barre syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan
Proc Natl Acad Sci U S A Yuki 101 31 11404 2004 10.1073/pnas.0402391101 Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome
J Exp Med Yuki 178 5 1771 1993 10.1084/jem.178.5.1771 A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure
N Engl J Med Fisher 255 2 57 1956 10.1056/NEJM195607122550201 An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia)
Brain Flachenecker 120 pt 10 1885 1997 10.1093/brain/120.10.1885 Power spectrum analysis of heart rate variability in Guillain-Barre syndrome: a longitudinal study
Clin Auton Res Flachenecker 10 4 185 2000 10.1007/BF02291354 Detection of serious bradyarrhythmias in Guillain-Barre syndrome: sensitivity and specificity of the 24-hour heart rate power spectrum
Lancet van Koningsveld 363 9404 192 2004 10.1016/S0140-6736(03)15324-X Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial
BMC Health Serv Res Winters 11 101 2011 10.1186/1472-6963-11-101 Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barre syndrome
Neurocrit Care Walgaard 26 1 6 2017 10.1007/s12028-016-0311-5 Tracheostomy or not: prediction of prolonged mechanical ventilation in Guillain-Barre syndrome [published online ahead of print August 18, 2016]
Neurology Kramer 84 8 e57 2015 10.1212/WNL.0000000000001296 Teaching video neuroimages: how to unmask respiratory strength confounded by facial diplegia
Lancet Cao-Lormeau 387 10027 1531 2016 10.1016/S0140-6736(16)00562-6 Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study
JMIR Res Protoc Yamaguchi 5 4 e210 2016 10.2196/resprot.6610 A prospective, multicenter, randomized phase II study to evaluate the efficacy and safety of eculizumab in patients with Guillain-Barre syndrome (GBS): protocol of Japanese eculizumab trial for GBS (JET-GBS)
※ AI-Helper는 부적절한 답변을 할 수 있습니다.